Cargando…
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study
BACKGROUND: Few data are available on programmed cell-death-protein-1–ligand-1 (PD-L1) expression on large-cell neuroendocrine carcinomas of the lung (LCNECs). We analyzed PD-L1 expression on tumor (TCs) and inflammatory cells (ICs) from LCNEC patients to assess relationships between this expression...
Autores principales: | Arpin, Dominique, Charpentier, Marie-Christine, Bernardi, Marie, Monnet, Isabelle, Boni, Aurelie, Watkin, Emmanuel, Goubin-Versini, Isabelle, Lamy, Régine, Gérinière, Laurence, Geier, Margaux, Forest, Fabien, Gervais, Radj, Madrosyk, Anne, Guisier, Florian, Serrand, Cécile, Locher, Chrystèle, Decroisette, Chantal, Fournel, Pierre, Auliac, Jean-Bernard, Jeanfaivre, Thierry, Letreut, Jacques, Doubre, Hélène, Francois, Geraldine, Piton, Nicolas, Chouaïd, Christos, Damotte, Diane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343361/ https://www.ncbi.nlm.nih.gov/pubmed/32684990 http://dx.doi.org/10.1177/1758835920937972 |
Ejemplares similares
-
Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
por: Auliac, Jean-Bernard, et al.
Publicado: (2020) -
Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14
por: Auliac, Jean-Bernard, et al.
Publicado: (2019) -
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020) -
Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
por: Auliac, Jean-Bernard, et al.
Publicado: (2020) -
Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
por: Martel-Lafay, Isabelle, et al.
Publicado: (2021)